digital coin exchanges, People searches

-Great potential of veterinary vaccines: The company is the leader of veterinary vaccines led by innovation, with over 15 vaccine varieties on the market and over 20 vaccine varieties under research. Its market share of blue-ear inactivated vaccine ranks first. Youbutai, the first animal brucellosis vaccine that meets the ideal standards of the World Health Organization, has been successfully launched and rapidly released. The freeze-dried inactivated African swine fever vaccine has also entered the stage of efficacy evaluation and testing, which is expected to inject vitality into the veterinary vaccine sector.-Accelerating the pace of internationalization: The company has established a sales network for veterinary chemicals that radiates to key global markets, and the sales revenue in overseas markets continues to rise, and the sales network for veterinary chemicals has been extended to veterinary vaccines, which has exerted a synergistic effect. In the future, overseas markets are expected to continue to expand and promote performance growth.-Veterinary chlortetracycline leader: Jinhe Bio is the largest producer of veterinary chlortetracycline in the world, with a production capacity of 55,000 tons/year, accounting for 51% of the global production capacity. After the sixth phase of the project is put into operation, it will increase production capacity, and part of it will be used for chlortetracycline production, further consolidating its leading position.

【 Expanded Title 】 The idea of buying Jinhe Bio may have the following points.The valuation advantage is obvious.According to the research report of Huasheng Securities, Jinhe Bio expects the net profit of returning to its mother in 2024-2026 to be 2.07/2.92/391 million yuan, corresponding to the pe(ttm) of 18.57/13.15/9.83x, while the average predicted PE (TTM) of comparable companies in 24-26 years is 23.46/18.89/11, respectively.

-Great potential of veterinary vaccines: The company is the leader of veterinary vaccines led by innovation, with over 15 vaccine varieties on the market and over 20 vaccine varieties under research. Its market share of blue-ear inactivated vaccine ranks first. Youbutai, the first animal brucellosis vaccine that meets the ideal standards of the World Health Organization, has been successfully launched and rapidly released. The freeze-dried inactivated African swine fever vaccine has also entered the stage of efficacy evaluation and testing, which is expected to inject vitality into the veterinary vaccine sector.-Improvement of profitability: In the first half of 2024, the overall gross profit margin was 33.3%, up by 3.4 percentage points year-on-year, and the net cash flow from operating activities reached 170 million yuan, up by 90.04% year-on-year, indicating that the company's profitability and cash flow were in good condition.-Improvement of profitability: In the first half of 2024, the overall gross profit margin was 33.3%, up by 3.4 percentage points year-on-year, and the net cash flow from operating activities reached 170 million yuan, up by 90.04% year-on-year, indicating that the company's profitability and cash flow were in good condition.